22-Jul-2020 - CureVac AG

CureVac Raises a Total of USD 640 Million in Private Financing Round

CureVac AG announced the closing of its latest private financing round, raising a total of USD 640 million (560 million Euros). The financing round included previously announced equity investments by the German government via the Kreditanstalt für Wiederaufbau (KfW) with USD 343 million and GSK with USD 171 million as well as additional new equity investments from Qatar Investment Authority (QIA) and a group of existing and new investors with approximately USD 126 million.

Facts, background information, dossiers
  • financing
  • CureVac
More about CureVac
  • News

    CureVac’s COVID-19 Vaccine Candidate Demonstrated Efficient Protection of Non-Human Primates During SARS-CoV-2 Challenge Infection

    CureVac N.V. announced the publication of preclinical data demonstrating the induction of robust antibody and T cell responses of its COVID-19 vaccine candidate, CVnCoV, in non-human primates. Furthermore, rhesus macaques were shown to be protected from challenge infection with SARS-CoV-2 f ... more

    CureVac Commences Global Pivotal Phase 2b/3 Trial

    CureVac N.V. announced that it has enrolled the first participant in the pivotal Phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled Phase 2b/3 trial called HERALD will assess the safety and efficacy of CVnCoV in adult ... more

    CureVac expands management board

    CureVac N.V. announced that Antony Blanc, PhD, was appointed Chief Business Officer and Chief Commercial Officer of CureVac. In this role, he will be responsible for building the network of partnerships that will support the growth of CureVac, for developing the competitiveness and commerci ... more

  • Companies

    CureVac AG

    CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 18 years’ expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the hum ... more